UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF INCOME - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2025	Mar. 31, 2024
Revenues:
Finance receivable interest income, including fees	$ 10,712	$ 11,035
Pharmaceutical development	963	279
Other	157	46
Total revenues	11,832	11,360
Costs and expenses:
Provision (benefit) for credit losses	(1,465)	5,297
Interest expense	1,130	1,256
Pharmaceutical manufacturing, research and development expense	758	530
Depreciation and amortization expense	19	514
General and administrative expense	3,277	2,684
Income from operations	8,113	1,079
Other income (expense), net
Unrealized net loss on warrants	(424)	(95)
Net loss on exercise and cancellation of warrants	0	(143)
Loss on sale of assets	(82)	0
Net loss on marketable investments	(105)	(231)
Realized gain on early payment of finance receivable	1,729	0
Loss on revaluation of finance receivables held for sale	(3,727)	0
Realized and unrealized foreign currency transaction gains	313	87
Income before income tax expense	5,817	697
Income tax expense	1,278	229
Net income	$ 4,539	$ 468
Net income per share
Basic (in dollars per share)	$ 0.37	$ 0.04
Diluted (in dollars per share)	$ 0.37	$ 0.04
Weighted average shares outstanding
Basic (in shares)	12,229,000	12,475,000
Diluted (in shares)	12,240,000	12,496,000